| 000 | 01711 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517070433.0 | ||
| 264 | 0 | _c20170403 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a1179-2027 | ||
| 024 | 7 |
_a10.1007/s40273-015-0356-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFraser, Ilanca | |
| 245 | 0 | 0 |
_aCost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. _h[electronic resource] |
| 260 |
_bPharmacoEconomics _cApr 2016 |
||
| 300 |
_a403-17 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xeconomics |
| 650 | 0 | 4 |
_aBenzimidazoles _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xeconomics |
| 650 | 0 | 4 |
_aFluorenes _xeconomics |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepacivirus _xgenetics |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 |
_aInterferon-alpha _xeconomics |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xeconomics |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aRecombinant Proteins _xeconomics |
| 650 | 0 | 4 |
_aRibavirin _xeconomics |
| 650 | 0 | 4 | _aSofosbuvir |
| 650 | 0 | 4 | _aSouth Africa |
| 650 | 0 | 4 |
_aUridine Monophosphate _xanalogs & derivatives |
| 700 | 1 | _aBurger, Johanita | |
| 700 | 1 | _aLubbe, Martie | |
| 700 | 1 | _aDranitsaris, George | |
| 700 | 1 | _aSonderup, Mark | |
| 700 | 1 | _aStander, Tienie | |
| 773 | 0 |
_tPharmacoEconomics _gvol. 34 _gno. 4 _gp. 403-17 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40273-015-0356-x _zAvailable from publisher's website |
| 999 |
_c25540811 _d25540811 |
||